BPC-157 — pharmacology
Molecular targets, mechanism of action, pharmacokinetics and interactions as characterised in humans.
§2Pharmacology
§2.1Molecular targets
Table 2. Molecular targets recorded for BPC-157, with the character of the interaction and the potency where the Institute holds it.
| Target | Interaction | Note |
|---|---|---|
| Mechanism not established | No defined receptor identified | Preclinical work implicates VEGFR2 transactivation, nitric-oxide-pathway modulation and FAK–paxillin signalling; none has been confirmed as a primary molecular target in human tissue |
§2.2Mechanism of action
The proposed mechanism is angiogenic and cytoprotective action through VEGF receptor 2 transactivation and nitric-oxide-pathway modulation, described extensively in rodent models of gastrointestinal, tendon, muscle, nerve and corneal injury. The Institute records that this literature is unusually concentrated in a small number of collaborating research groups, that independent replication outside that network is limited, and that no molecular target has been established by conventional target-validation methods. The mechanistic account should therefore be read as a hypothesis with preclinical support, not as established pharmacology.[1,2]
§2.3Pharmacokinetics
No human pharmacokinetic characterisation of BPC-157 has been identified. In the absence of a half-life, a volume of distribution and a clearance estimate, no dosing interval used in practice can be related to any exposure that produced an effect in any study, and the Institute records this as a first-order gap rather than a detail.
§2.4Interactions
- Not characterised
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Stupnisek M, Suran J, Barisic I, Dzidic S, Prkacin I. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 2011;17(16):1612–1632. doi:10.2174/138161211796196954 · PMID 21548867
- Bhattacharyya S, Wang J, Kaplan RM. Quality of peptide products obtained from unregulated online suppliers: an analytical survey. Journal of Pharmaceutical Sciences 2024;113(4):1102–1110. doi:10.1016/j.xphs.2023.11.021 Cited by the Institute as an indicative analytical survey; sample frame was not random.
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.